Show simple item record

dc.contributor.authorKawashima, H
dc.contributor.authorGao, C
dc.contributor.authorTakahashi, K
dc.contributor.authorTomaniak, M
dc.contributor.authorOno, M
dc.contributor.authorHara, H
dc.contributor.authorWang, R
dc.contributor.authorChichareon, P
dc.contributor.authorSuryapranata, H
dc.contributor.authorWalsh, S
dc.contributor.authorCotton, J
dc.contributor.authorKoning, R
dc.contributor.authorRensing, B
dc.contributor.authorWykrzykowska, J
dc.contributor.authorDe Winter, RJ
dc.contributor.authorGarg, S
dc.contributor.authorAnderson, R
dc.contributor.authorHamm, C
dc.contributor.authorSteg, PG
dc.contributor.authorOnuma, Y
dc.contributor.authorSerruys, PW
dc.date.accessioned2021-09-28T08:50:49Z
dc.date.available2021-09-28T08:50:49Z
dc.date.issued2020-06-22
dc.identifier.citationKawashima, H., Gao, C., Takahashi, K. et al. (2020) Comparative assessment of predictive performance of PRECISE-DAPT, CRUSADE, and ACUITY scores in risk stratifying 30-day bleeding events. Thrombosis and Haemostasis, 120(07), 1087-1095 DOI: 10.1055/s-0040-1712449en
dc.identifier.issn0340-6245en
dc.identifier.pmid32572864 (pubmed)
dc.identifier.doi10.1055/s-0040-1712449en
dc.identifier.urihttp://hdl.handle.net/2436/624374
dc.description© 2020 The Authors. Published by Georg Thieme Verlag. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0040-1712449en
dc.description.abstractBackground The utility of the PRECISE-DAPT score in predicting short-term major bleeding, either alone, or in comparison with the CRUSADE and ACUITY scores, has not been investigated. This analysis compared the predictive performances of the three bleeding scores in stratifying the risk of 30-day major bleeding postpercutaneous coronary intervention in patients with dual-antiplatelet therapy. Methods In this post hoc subanalysis of the GLOBAL LEADERS trial, the primary safety objective (bleeding according to the Bleeding Academic Research Consortium [BARC] criteria [type 3 or 5]) was assessed at 30 days according to the three scores in the overall population, and in patients with acute (ACS) and chronic coronary syndrome (CCS). Results In a total of 15,968 patients, we calculated all three scores in 14,709 (92.1%). Irrespective of clinical presentation, the PRECISE-DAPT (c-statistics: 0.648, 0.653, and 0.641, respectively), CRUSADE (c-statistics: 0.641, 0.639, and 0.644, respectively), and ACUITY (c-statistics: 0.633, 0.638, and 0.623, respectively) scores were no significant between-score differences in discriminatory performance for BARC 3 or 5 bleeding up to 30 days, and similarly the PRECISE-DAPT score had a comparable discriminative capacity according to the integrated discrimination improvement when compared with the other scores. In ACS, the CRUSADE score had a poor calibration ability (Hosmer-Lemeshow goodness-of-fit [GOF] chi-square = 15.561, p = 0.049), whereas in CCS, the PRECISE-DAPT score had poor calibration (GOF chi-square = 15.758, p = 0.046). Conclusion The PRECISE-DAPT score might be clinically useful in the overall population and ACS patients for the prediction of short-term major bleeding considering its discriminative and calibration abilities.en
dc.description.sponsorshipThe GLOBAL LEADERS study was sponsored by the European Clinical Research Institute, which received funding from AstraZeneca, Biosensors International, and the Medicines Company.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherGeorg Thieme Verlagen
dc.relation.urlhttps://www.thieme-connect.de/products/ejournals/html/10.1055/s-0040-1712449en
dc.rightsLicence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectbleeding scoresen
dc.subjectmajor bleedingen
dc.subjectpercutaneous coronary interventionen
dc.subjectdual-antiplatelet therapyen
dc.subjectdiscriminationen
dc.subjectcalibrationen
dc.subject.meshHumans
dc.subject.meshChronic Disease
dc.subject.meshHemorrhage
dc.subject.meshTreatment Outcome
dc.subject.meshRisk Assessment
dc.subject.meshRisk Factors
dc.subject.meshPredictive Value of Tests
dc.subject.meshDecision Support Techniques
dc.subject.meshTime Factors
dc.subject.meshAged
dc.subject.meshMiddle Aged
dc.subject.meshFemale
dc.subject.meshMale
dc.subject.meshCoronary Artery Disease
dc.subject.meshAcute Coronary Syndrome
dc.subject.meshPercutaneous Coronary Intervention
dc.subject.meshDual Anti-Platelet Therapy
dc.titleComparative assessment of predictive performance of PRECISE-DAPT, CRUSADE, and ACUITY scores in risk stratifying 30-day bleeding eventsen
dc.typeJournal articleen
dc.identifier.eissn2567-689X
dc.identifier.journalThrombosis and Haemostasisen
dc.date.updated2021-09-27T10:22:56Z
dc.contributor.institutionDepartment of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, The Netherlands.
pubs.place-of-publicationGermany
dc.date.accepted2020-04-19
rioxxterms.funderAstraZeneca, Biosensors International, and the Medicines Companyen
rioxxterms.identifier.projectUOW28092021JCen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2021-09-28en
dc.source.volume120
dc.source.issue7
dc.source.beginpage1087
dc.source.endpage1095
dc.description.versionPublished version
refterms.dateFCD2021-09-28T08:50:26Z
refterms.versionFCDVoR
refterms.dateFOA2021-09-28T08:50:50Z


Files in this item

Thumbnail
Name:
Comparative Assessment of ...
Size:
304.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International